Dr. Ken Blount, cofounder and director of biology at BioRelix Inc., will lead an one-hour discussion on Monday, January 13th at 1pm, location TBA.
There are eight open slots for this event. Please email Tenaya Vallery (tenaya.vallery@yale.edu) to secure a spot.
Career Mentor's Bio: Dr. Ken Blount earned his Ph.D. at the University of Colorado, studying the mechanisms of RNA enzymes (ribozymes). He went onto an NIH Post-Doctoral Fellowship at the University of California at San Diego, studying RNA-targeting small-molecular antibiotics. In 2004, he contacted Ron Breaker at Yale regarding Ron's interest in forming a startup focused on developing antibiotics that target RNA riboswitches. In 2005, he joined Ron's team, leading the effort to found BioRelix. BioRelix secured seed-round investment in 2006 and Series A investment in 2007 and is currently developing novel antibiotics that target riboswitches. BioRelix has also formed a research collaboration with Merck Pharmaceuticals to leverage the unique riboswitch target portfolio.
No comments:
Post a Comment